CD274 and lung carcinoma: Studies have shown that the expression of PD-L1 in the neoadjuvant chemotherapy group is higher than that in the nonneoadjuvant chemotherapy group, which may be due to the activation of the specific immune response mechanism of lung cancer, resulting in the upregulation of PD-L1 expression [21, 39].